---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-112926"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:24:21.121558+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tarsus Pharma appoints Jeff Farrow as CFO and Chief Strategy Officer; Leo Greenstein departs

## Summary
- Leo Greenstein left as CFO effective April 24, 2023; employment continues through June 15, 2023.
- Jeff Farrow appointed CFO and Chief Strategy Officer effective April 24, 2023; previously CFO at Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics.
- Farrow receives $500,000 base salary, $100,000 signing bonus (paid in two tranches), and 40% annual bonus target.
- Equity awards: RSUs and options each with $1.5M target value; RSUs vest 25% annually over 4 years starting June 15, 2024.
- Severance: 9 months base salary (non-CIC) or 12 months base plus accelerated vesting and prorated bonus (CIC).

## SEC filing metadata
- accession: 0001193125-23-112926
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000119312523112926/0001193125-23-112926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000119312523112926/d470193d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-112926
- JSON: https://secwatch.observer/filing/0001193125-23-112926.json
- Plain text: https://secwatch.observer/filing/0001193125-23-112926.txt

## Key facts
- Executive change
  Jeff Farrow was appointed as Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Chief Strategy Officer
  source text: The Company also announced the appointment of Jeff Farrow as the Company’s Chief Financial Officer and Chief Strategy Officer, also effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312523112926/0001193125-23-112926-index.htm
- Executive change
  Leo Greenstein changed role as Chief Financial Officer at Tarsus Pharmaceuticals, Inc..
  - Action: leaving his role
  - Role: Chief Financial Officer
  source text: On April 24, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Leo Greenstein would be leaving his role as the Company’s Chief Financial Officer (the “Transition”), effective as of April 24, 2023 (the “Transition Date”) and leaving his employment with the Company on June 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312523112926/0001193125-23-112926-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.